dievini Hopp Biotech Holding
19
38M
7
1.12
2
0.63
4
- Stages of investment
- Areas of investment
Summary
The leading representative office of defined Corporate Investor is situated in the Walldorf. The fund was located in Europe if to be more exact in Germany.
The standard case for the fund is to invest in rounds with 2 partakers. Despite the dievini Hopp Biotech Holding, startups are often financed by Wellington Partners, OH Beteiligungen, DH Capital. The meaningful sponsors for the fund in investment in the same round are Wellington Partners, AT Impf, Sigma Group. In the next rounds fund is usually obtained by Wellington Partners, AT Impf, Bill & Melinda Gates Foundation.
Among the most popular portfolio startups of the fund, we may highlight CureVac, Apogenix, Novaliq. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Germany. The fund has exact preference in some founders of portfolio startups. Among the most popular fund investment industries, there are Therapeutics, Biopharma. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year. This dievini Hopp Biotech Holding works on 22 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2016. The typical startup value when the investment from dievini Hopp Biotech Holding is more than 1 billion dollars. The high activity for fund was in 2012. Speaking about the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations.
This organization was formed by Christof Hettich, Friedrich Bohlen. The overall number of key employees were 2.
Investments analytics
Analytics
- Total investments
- 19
- Lead investments
- 2
- Exits
- 4
- Rounds per year
- 1.12
- Follow on index
- 0.63
- Investments by industry
- Biotechnology (19)
- Therapeutics (11)
- Health Care (10)
- Pharmaceutical (8)
- Medical (6) Show 3 more
- Investments by region
-
- Germany (18)
- Switzerland (1)
- Peak activity year
- 2020
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Avg. valuation at time of investment
- 234M
- Group Appearance index
- 0.37
- Avg. company exit year
- 11
- Strategy success index
- 0.38
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| immatics biotechnologies | 21 Sep 2010 | Biotechnology, Medical, Therapeutics | Late Stage Venture | 63M | Germany, Baden-Württemberg, Germany |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.